查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1709467

呼吸道合胞病毒治疗市场，依治疗类型、剂型、年龄层、配销通路、国家和地区 - 2025 年至 2032 年全球产业分析、市场规模、市场份额和预测

Respiratory Syncytial Virus Therapeutics Market, By Treatment Type, By Dosage Form, By Age Group, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 299 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年呼吸道合胞病毒治疗市场规模价值 15.9032 亿美元，2025 年至 2032 年的复合年增长率为 15.50%。

诊断技术的进步有助于早期发现和及时介入。北美和欧洲凭藉其强大的医疗保健基础设施和较高的认知度占据主导地位，而新兴经济体则显示出日益增长的采用率。生物技术公司和医疗保健组织之间的合作进一步支持了市场的成长。预计成本效益疗法的引入将提高全球范围内的可及性，确保更好地管理疾病。

呼吸道合胞病毒治疗市场-市场动态

越来越多地采用长效单株抗体来保护婴儿免受呼吸道合胞病毒感染。

长效单株抗体在婴儿呼吸道合胞病毒防护中的应用日益增多，这是呼吸道合胞病毒治疗市场的主要驱动力。传统的单株抗体，例如帕利珠单抗，需要每月服用一次，限制了其可及性和依从性。然而，像 Nirsevimab 这样的较新的长效抗体只需单剂量就能提供更长的保护，使其更加方便和具有成本效益。政府和医疗保健组织正在积极推荐高风险婴儿接受这些疗法，以减少与呼吸道合胞病毒相关的住院。新生儿和早产儿呼吸道合胞病毒感染负担沉重，导致免疫接种计画扩大。此外，长效单株抗体的监管批准和资金投入正在增加其在已开发市场和新兴市场的可用性。随着这些疗法越来越融入常规婴儿护理，预计它们将显着推动市场成长。

呼吸道合胞病毒治疗市场—关键见解

根据我们的研究分析师的分析，预计全球市场在预测期内（2025-2032 年）的年复合成长率约为 15.50%

根据治疗类型细分，预计单株抗体将在 2024 年占据最大市场份额

根据剂型细分，注射剂是 2024 年的主要剂型

根据年龄组细分，婴幼儿是 2024 年领先的年龄组

根据配销通路细分，医院和诊所是 2024 年领先的配销通路

按地区划分，北美是 2024 年最大的收入来源

呼吸道合胞病毒治疗市场-区隔分析：

全球呼吸道合胞病毒治疗市场根据治疗类型、剂型、年龄层、配销通路和地区进行细分。

根据治疗类型，市场分为三类：抗病毒药物、单株抗体和疫苗。单株抗体在呼吸道合胞病毒 (RSV) 治疗市场中占据主导地位，因为它们能有效预防严重的 RSV 感染，尤其是在婴儿和老年人等高风险族群中。帕利珠单抗已被广泛使用多年，而最近批准的 Nirsevimab 等长效单株抗体进一步加强了这一领域。这些治疗提供了被动免疫，减少了与呼吸道合胞病毒相关的住院和併发症。 RSV 感染负担的持续加重，以及政府建议弱势群体使用单株抗体，刺激了需求。製药公司继续投资开发具有更高疗效和更长作用时间的下一代单株抗体。此外，这些疗法的高成本对市场收入贡献巨大。由于强大的医疗保健基础设施和报销政策，北美和欧洲在采用方面处于领先地位。随着新的抗体製剂获得监管部门的批准，预计该领域将在 RSV 治疗市场中保持主导地位。

根据剂型，市场分为三类：口服、注射和吸入。由于单株抗体和疫苗的广泛使用（主要透过注射给药），注射剂在呼吸道合胞病毒 (RSV) 治疗市场中占据主导地位。帕利珠单抗和尼尔塞维单抗等单株抗体以及新批准的老年人呼吸道合胞病毒疫苗都依靠注射剂型进行有效传递。此途径确保了精确的剂量、快速的吸收和长期的保护，使其成为高风险族群的首选。婴儿和老年人严重呼吸道合胞病毒感染的发生率不断上升，导致注射治疗的应用增加。此外，政府免疫计划和医院规程都支持注射呼吸道合胞病毒疗法，进一步推动了这一领域的发展。由于强大的医疗保健基础设施和较高的疫苗覆盖率，北美和欧洲在註射呼吸道合胞病毒疗法方面处于领先地位。随着更多长效单株抗体和呼吸道合胞病毒疫苗获得批准，注射剂市场预计将保持主导地位。

呼吸道合胞病毒治疗市场-地理洞察

由于知名度高、医疗保健基础设施强大以及单株抗体和疫苗的广泛采用，北美在呼吸道合胞病毒 (RSV) 治疗市场占据主导地位。美国在该地区处于领先地位，拥有政府支持的免疫计划和监管部门批准的先进呼吸道合胞病毒疗法，如 Nirsevimab 和老年人呼吸道合胞病毒疫苗。婴儿和老年族群中因呼吸道合胞病毒相关疾病住院的人数不断增加，推动了对有效治疗的需求。此外，各大製药公司正在投资研发，以推出下一代单株抗体。优惠的报销政策和高额的医疗保健支出进一步支持了该地区的市场成长。

美国凭藉其先进的医疗保健基础设施、高度的疾病意识和强有力的政府支持，占据呼吸道合胞病毒 (RSV) 治疗市场的最大份额。美国疾病管制与预防中心 (CDC) 和美国食品药物管理局 (FDA) 已批准用于老年人的呼吸道合胞病毒疫苗和婴儿保护的长效单株抗体（如 Nirsevimab），从而推动了该疫苗的广泛应用。呼吸道合胞病毒相关住院人数不断增加，尤其是婴儿和老年人，这增加了对有效治疗的需求。政府支持的免疫计划和报销政策进一步促进了市场成长。此外，製药公司正在大力投资研究和临床试验，以开发下一代 RSV 疗法。该国的高医疗支出和健全的监管框架确保了市场持续扩张。

呼吸道合胞病毒治疗市场-竞争格局：

呼吸道合胞病毒 (RSV) 治疗市场的竞争格局以密集的研究和开发 (R&D) 努力、策略合作和监管部门批准为特点。领先的製药公司专注于开发单株抗体、疫苗和抗病毒药物，以应对日益加重的 RSV 感染负担。市场由阿斯特捷利康、赛诺菲、辉瑞、葛兰素史克和 Moderna 主导，这些公司已经推出或正在开发创新的 RSV 疗法。

主要参与者正在利用策略合作伙伴关係和收购来扩大其产品组合，例如辉瑞收购 ReViral 以进行 RSV 抗病毒开发。 Nirsevimab 等长效单株抗体和老年人呼吸道合胞病毒疫苗的核准加剧了竞争。公司也专注于临床试验、政府合作和定价策略以巩固其市场地位。随着对呼吸道合胞病毒预防和治疗的需求不断增加，随着新进业者和先进的治疗解决方案的出现，竞争格局预计将发生变化。

最新动态：

2024 年 2 月，葛兰素史克公司宣布，美国食品药物管理局 (FDA) 对其呼吸道合胞病毒 (RSV) 联合疫苗的适应症扩大至 50 至 59 岁患 RSV 疾病风险较高的人群的申请给予优先审查。

2023年5月，辉瑞表示，美国食品药物管理局（FDA）核准其二价RSV预融合F（RSVpreF）疫苗ABRYSVO，用于预防60岁以上人口由RSV引起的下呼吸道疾病。这一策略促进了公司的收入成长。

目录

第 1 章：呼吸道合胞病毒治疗市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 呼吸道合胞病毒治疗市场片段（依治疗类型）
    • 呼吸道合胞病毒治疗市场（依剂型划分）
    • 呼吸道合胞病毒治疗市场按年龄层细分
    • 呼吸道合胞病毒治疗市场片段（依配销通路）
    • 呼吸道合胞病毒治疗市场（依国家/地区）
    • 呼吸道合胞病毒治疗市场（按地区）
  • 竞争洞察

第三章：呼吸道合胞病毒治疗关键市场趋势

  • 呼吸道合胞病毒治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 呼吸道合胞病毒治疗市场限制
    • 市场限制的影响分析
  • 呼吸道合胞病毒治疗市场机会
  • 呼吸道合胞病毒治疗市场未来趋势

第四章：呼吸道合胞病毒治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：呼吸道合胞病毒治疗市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：呼吸道合胞病毒治疗市场格局

  • 2024年呼吸道合胞病毒治疗市占分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：呼吸道合胞病毒治疗市场－依治疗类型

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 抗病毒药物
    • 单株抗体
    • 疫苗

第八章：呼吸道合胞病毒治疗市场－按剂型

  • 概述
    • 按剂型分類的细分市场份额分析
    • 口服
    • 注射剂
    • 吸入

第九章：呼吸道合胞病毒治疗市场－依年龄组

  • 概述
    • 按年龄组别分類的细分份额分析
    • 婴幼儿
    • 成年人
    • 老年人（65岁以上）

第 10 章：呼吸道合胞病毒治疗市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院和诊所
    • 零售药局
    • 网路药局

第 11 章：呼吸道合胞病毒治疗市场-按地区

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美呼吸道合胞病毒治疗主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模和预测，按治疗类型
    • 北美市场规模及预测（按剂型）
    • 北美市场规模及预测（按年龄层）
    • 北美市场规模及预测（按配销通路）
    • 美国
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲呼吸道合胞病毒治疗主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（按治疗类型）
    • 欧洲市场规模及预测（按剂型）
    • 欧洲市场规模及预测（依年龄层）
    • 欧洲市场规模及预测（按配销通路）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区呼吸道合胞病毒治疗主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依治疗类型）
    • 亚太地区市场规模及预测（依剂型划分）
    • 亚太地区市场规模及预测（依年龄层）
    • 亚太地区市场规模及预测（按配销通路）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲呼吸道合胞病毒治疗主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按治疗类型）
    • 拉丁美洲市场规模及预测（以剂型划分）
    • 拉丁美洲市场规模及预测（按年龄层）
    • 拉丁美洲市场规模及预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲呼吸道合胞病毒治疗主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依治疗类型）
    • MEA 市场规模及预测（以剂型）
    • MEA 市场规模及预测（依年龄层）
    • MEA 市场规模及预测（依配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 12 章：呼吸道合胞病毒治疗产业主要供应商分析

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • AstraZeneca plc
    • Sanofi SA
    • Pfizer Inc.
    • Moderna, Inc.
    • GSK plc
    • Merck & Co., Inc.
    • Johnson & Johnson
    • Novavax, Inc.
    • Bavarian Nordic A/S
    • Enanta Pharmaceuticals, Inc.
    • BioNTech SE
    • Meissa Vaccines, Inc.
    • Codagenix, Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Vaxart, Inc.
    • Icosavax, Inc.

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4937

REPORT HIGHLIGHT

Respiratory Syncytial Virus Therapeutics Market size was valued at US$ 1,590.32 Million in 2024, expanding at a CAGR of 15.50% from 2025 to 2032.

The Respiratory Syncytial Virus (RSV) therapeutics market focuses on treatments and preventive solutions for RSV infections, which primarily affect infants, older adults, and immunocompromised individuals. This market includes antiviral drugs, monoclonal antibodies, and vaccines aimed at reducing disease severity and transmission. The increasing prevalence of RSV, along with rising hospitalizations, has driven demand for effective therapies. Governments and pharmaceutical companies are investing in research to develop advanced treatments, including long-acting monoclonal antibodies and novel antivirals. Regulatory approvals for RSV vaccines, especially for high-risk groups, have expanded the market.

Advancements in diagnostic techniques support early detection and timely intervention. North America and Europe dominate due to strong healthcare infrastructure and high awareness while emerging economies show growing adoption. Market growth is further supported by collaborations between biotech firms and healthcare organizations. The introduction of cost-effective therapies is expected to enhance accessibility worldwide, ensuring better disease management.

Respiratory Syncytial Virus Therapeutics Market- Market Dynamics

Increasing adoption of long-acting monoclonal antibodies for infant RSV protection.

The increasing adoption of long-acting monoclonal antibodies for infant RSV protection is a key driver of the RSV therapeutics market. Traditional monoclonal antibodies, such as Palivizumab, required monthly dosing, limiting their accessibility and compliance. However, newer long-acting antibodies like Nirsevimab offer extended protection with a single dose, making them more convenient and cost-effective. Governments and healthcare organizations are actively recommending these therapies for high-risk infants to reduce RSV-related hospitalizations. The high burden of RSV infections in newborns and premature babies has led to expanded immunization programs. Additionally, regulatory approvals and funding for long-acting monoclonal antibodies are increasing their availability in developed and emerging markets. As these therapies become more integrated into routine infant care, they are expected to drive market growth significantly.

Respiratory Syncytial Virus Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.50% over the forecast period (2025-2032)

Based on Treatment Type segmentation, monoclonal antibodies were predicted to show maximum market share in the year 2024

Based on Dosage Form segmentation, injectable was the leading Dosage Form in 2024

Based on Age Group segmentation, Infants & Young Children was the leading Age Group in 2024

Based on Distribution Channel segmentation, Hospitals & Clinics was the leading Distribution Channel in 2024

based on region, North America was the leading revenue generator in 2024

Respiratory Syncytial Virus Therapeutics Market- Segmentation Analysis:

The Global Respiratory Syncytial Virus Therapeutics Market is segmented based on Treatment Type, Dosage Form, Age Group, Distribution Channel, and Region.

The market is divided into three categories based on Treatment Type: Antiviral Drugs, Monoclonal Antibodies, and Vaccines. The monoclonal antibodies segment dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to their effectiveness in preventing severe RSV infections, especially in high-risk groups like infants and older adults. Palivizumab has been widely used for years, and the recent approval of long-acting monoclonal antibodies such as Nirsevimab has further strengthened this segment. These treatments provide passive immunity, reducing RSV-related hospitalizations and complications. The increasing burden of RSV infections, along with government recommendations for monoclonal antibody use in vulnerable populations, has fueled demand. Pharmaceutical companies continue to invest in developing next-generation monoclonal antibodies with improved efficacy and longer duration of action. Additionally, the high cost of these therapies contributes significantly to market revenue. North America and Europe lead in adoption due to strong healthcare infrastructure and reimbursement policies. As new antibody formulations receive regulatory approvals, this segment is expected to maintain its dominance in the RSV therapeutics market.

The market is divided into three categories based on Dosage Form: Oral, Injectable, and Inhalation. The injectable segment dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to the widespread use of monoclonal antibodies and vaccines, which are primarily administered via injection. Monoclonal antibodies like Palivizumab and Nirsevimab, as well as newly approved RSV vaccines for older adults, rely on injectable formulations for effective delivery. This route ensures precise dosing, rapid absorption, and prolonged protection, making it the preferred choice for high-risk populations. The rising incidence of severe RSV infections among infants and older adults has led to increased adoption of injectable treatments. Additionally, government immunization programs and hospital protocols favor injectable RSV therapies, further boosting this segment. North America and Europe lead in injectable RSV therapeutics due to strong healthcare infrastructure and high vaccine coverage. As more long-acting monoclonal antibodies and RSV vaccines gain approval, the injectable segment is expected to maintain its dominance.

Respiratory Syncytial Virus Therapeutics Market- Geographical Insights

North America dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to high awareness, strong healthcare infrastructure, and widespread adoption of monoclonal antibodies and vaccines. The U.S. leads the region, with government-backed immunization programs and regulatory approvals for advanced RSV therapies like Nirsevimab and RSV vaccines for older adults. Increasing RSV-related hospitalizations among infants and elderly populations have driven demand for effective treatments. Additionally, major pharmaceutical companies are investing in research and development to introduce next-generation monoclonal antibodies. Favorable reimbursement policies and high healthcare spending further support market growth in the region.

The United States holds the largest share of the Respiratory Syncytial Virus (RSV) therapeutics market due to its advanced healthcare infrastructure, high disease awareness, and strong government support. The CDC and FDA have approved RSV vaccines for older adults and long-acting monoclonal antibodies like Nirsevimab for infant protection, driving widespread adoption. Rising RSV-related hospitalizations, particularly among infants and the elderly, have increased demand for effective treatments. Government-backed immunization programs and reimbursement policies further boost market growth. Additionally, pharmaceutical companies are heavily investing in research and clinical trials to develop next-generation RSV therapeutics. The country's high healthcare spending and robust regulatory framework ensure continued market expansion.

Respiratory Syncytial Virus Therapeutics Market- Competitive Landscape:

The competitive landscape of the Respiratory Syncytial Virus (RSV) therapeutics market is characterized by intense research and development (R&D) efforts, strategic collaborations, and regulatory approvals. Leading pharmaceutical companies focus on developing monoclonal antibodies, vaccines, and antiviral drugs to address the growing burden of RSV infections. The market is dominated by AstraZeneca, Sanofi, Pfizer, GSK, and Moderna, which have introduced or are developing innovative RSV therapeutics.

Key players are leveraging strategic partnerships and acquisitions to expand their product portfolios, as seen in Pfizer's acquisition of ReViral for RSV antiviral development. The approval of long-acting monoclonal antibodies like Nirsevimab and RSV vaccines for older adults has intensified competition. Companies are also focusing on clinical trials, government collaborations, and pricing strategies to strengthen their market position. With increasing demand for RSV prevention and treatment, the competitive landscape is expected to evolve with new entrants and advanced therapeutic solutions.

Recent Developments:

In February 2024, GSK plc announced that the U.S. Food and Drug Administration (FDA) granted priority review for an application to expand the indication of its combined respiratory syncytial virus (RSV) vaccine to individuals aged 50 to 59 at higher risk of RSV illness.

In May 2023, Pfizer Inc. stated that the U.S. Food and Drug Administration (FDA) approved ABRYSVO, its bivalent RSV prefusion F (RSVpreF) vaccine, for preventing lower respiratory tract illness caused by RSV in individuals aged 60 and older. This strategy has contributed to the company's revenue growth.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AstraZeneca plc
  • Sanofi S.A.
  • Pfizer Inc.
  • Moderna, Inc.
  • GSK plc
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Novavax, Inc.
  • Bavarian Nordic A/S
  • Enanta Pharmaceuticals, Inc.
  • BioNTech SE
  • Meissa Vaccines, Inc.
  • Codagenix, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Vaxart, Inc.
  • Icosavax, Inc.

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antiviral Drugs
  • Monoclonal Antibodies
  • Vaccines

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Inhalation

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

  • Infants & Young Children
  • Adults
  • Older Adults (65+ years)

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Clinics
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Respiratory Syncytial Virus Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Respiratory Syncytial Virus Therapeutics Market Snippet by Treatment Type
    • 2.1.2. Respiratory Syncytial Virus Therapeutics Market Snippet by Dosage Form
    • 2.1.3. Respiratory Syncytial Virus Therapeutics Market Snippet by Age Group
    • 2.1.4. Respiratory Syncytial Virus Therapeutics Market Snippet by Distribution Channel
    • 2.1.5. Respiratory Syncytial Virus Therapeutics Market Snippet by Country
    • 2.1.6. Respiratory Syncytial Virus Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Respiratory Syncytial Virus Therapeutics Key Market Trends

  • 3.1. Respiratory Syncytial Virus Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Respiratory Syncytial Virus Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Respiratory Syncytial Virus Therapeutics Market Opportunities
  • 3.4. Respiratory Syncytial Virus Therapeutics Market Future Trends

4. Respiratory Syncytial Virus Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Respiratory Syncytial Virus Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Respiratory Syncytial Virus Therapeutics Market Landscape

  • 6.1. Respiratory Syncytial Virus Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Respiratory Syncytial Virus Therapeutics Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
    • 7.1.2. Antiviral Drugs
    • 7.1.3. Monoclonal Antibodies
    • 7.1.4. Vaccines

8. Respiratory Syncytial Virus Therapeutics Market - By Dosage Form

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectable
    • 8.1.4. Inhalation

9. Respiratory Syncytial Virus Therapeutics Market - By Age Group

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Age Group, 2024 & 2032 (%)
    • 9.1.2. Infants & Young Children
    • 9.1.3. Adults
    • 9.1.4. Older Adults (65+ years)

10. Respiratory Syncytial Virus Therapeutics Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 10.1.2. Hospitals & Clinics
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Respiratory Syncytial Virus Therapeutics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. The U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Respiratory Syncytial Virus Therapeutics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AstraZeneca plc
    • 12.2.2. Sanofi S.A.
    • 12.2.3. Pfizer Inc.
    • 12.2.4. Moderna, Inc.
    • 12.2.5. GSK plc
    • 12.2.6. Merck & Co., Inc.
    • 12.2.7. Johnson & Johnson
    • 12.2.8. Novavax, Inc.
    • 12.2.9. Bavarian Nordic A/S
    • 12.2.10. Enanta Pharmaceuticals, Inc.
    • 12.2.11. BioNTech SE
    • 12.2.12. Meissa Vaccines, Inc.
    • 12.2.13. Codagenix, Inc.
    • 12.2.14. Alnylam Pharmaceuticals, Inc.
    • 12.2.15. Vaxart, Inc.
    • 12.2.16. Icosavax, Inc.

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us